Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,totalCurrentAssets,netReceivables,longTermDebt,accountsPayable,intangibleAssets,shortLongTermDebt,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,changeToAccountReceivables,changeToNetincome,totalCashflowsFromInvestingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsTrailingTwelveMonths,epsForward,epsCurrentYear,priceEpsCurrentYear,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,forwardPE,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2021) 4","Short Ratio (Jul 14, 2021) 4","Short % of Float (Jul 14, 2021) 4","Short % of Shares Outstanding (Jul 14, 2021) 4","Shares Short (prior month Jun 14, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,HGEN,17023000.0,59083700,59934000,,-65567000,,-65567000,4948000,486000,-64396000,-64396000,,-19000,,,,0,486000,64882000,0,-1171000,,-65567000,-65567000,456966000.0,81825000.0,17023000.0,7045000.0,98848000.0,54000.0,-439997000.0,4126000.0,90000.0,92892000.0,53255000.0,98758000.0,5010000.0,24444000.0,43412000.0,,,32101000.0,24444000.0,60979000.0,2142000.0,36535000.0,25155000.0,-35824000.0,-5010000.0,510000.0,,45503000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,16.71,1630526403,0.12999916,16.3752,16.91,16.12,579568,USD,NCM,987288576,-14400000,False,False,PRE,2,0.78407216,16.12 - 16.91,us_market,0,"Humanigen, Inc.",16.58,0.0,0.0,10,14,finmb_6099166,NasdaqCM,"Humanigen, Inc.",USD,1119707,859085,9.209999,1.2279999,7.5 - 29.2,-12.490002,-0.42773977,7.5,29.2,1600041600,1620921660,1628798400,1629144000,-3.437,4.11,0.04,417.75,0.317,16.589714,0.120285034,0.007250579,17.594275,-0.88427544,-0.050259273,4.065693,52.71293,15,America/New_York,EDT,-2.37,,,29.2,7.5,16.59,17.59,1.12M,859.09k,59.08M,,44.37M,23.35%,39.16%,7.49M,5.47,19.83%,12.69%,7.16M,,,,,,0.00%,"Sep 13, 2020",,1:5,"Sep 13, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-18,864.29%",-189.54%,"-41,589.92%",798k,0.02,,312k,,-152.64M,-3.44,,92.89M,1.57,24.44M,143.59,1.85,0.32,-105.07M,-53.72M,Value,94005,Healthcare,10,"Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.",Burlingame,650 243 3100,CA,1609372800,United States,http://www.humanigen.com,86400,533 Airport Boulevard,Biotechnology,Suite 400
t-1,HGEN,45525000.0,59083700,28495000,,-32295000,,-32295000,4112000,312000,-32295000,-32295000,,-19000,,,,0,312000,32607000,0,0,,-32295000,-32295000,419923000.0,22757000.0,45545000.0,3874000.0,68302000.0,52000.0,-374430000.0,2342000.0,70000.0,67737000.0,20415000.0,68212000.0,,,13078000.0,20000.0,,4335000.0,1000.0,1000.0,3699000.0,36535000.0,-23694000.0,-23695000.0,-5010000.0,566000.0,,47797000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,16.71,1630526403,0.12999916,16.3752,16.91,16.12,579568,USD,NCM,987288576,-14400000,False,False,PRE,2,0.78407216,16.12 - 16.91,us_market,0,"Humanigen, Inc.",16.58,0.0,0.0,10,14,finmb_6099166,NasdaqCM,"Humanigen, Inc.",USD,1119707,859085,9.209999,1.2279999,7.5 - 29.2,-12.490002,-0.42773977,7.5,29.2,1600041600,1620921660,1628798400,1629144000,-3.437,4.11,0.04,417.75,0.317,16.589714,0.120285034,0.007250579,17.594275,-0.88427544,-0.050259273,4.065693,52.71293,15,America/New_York,EDT,-2.37,,,29.2,7.5,16.59,17.59,1.12M,859.09k,59.08M,,44.37M,23.35%,39.16%,7.49M,5.47,19.83%,12.69%,7.16M,,,,,,0.00%,"Sep 13, 2020",,1:5,"Sep 13, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-18,864.29%",-189.54%,"-41,589.92%",798k,0.02,,312k,,-152.64M,-3.44,,92.89M,1.57,24.44M,143.59,1.85,0.32,-105.07M,-53.72M,Value,94005,Healthcare,10,"Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.",Burlingame,650 243 3100,CA,1609372800,United States,http://www.humanigen.com,86400,533 Airport Boulevard,Biotechnology,Suite 400
t-2,HGEN,77250000.0,59083700,22416000,,-30751000,,-30751000,8331000,0,-30747000,-30747000,,-3000,,,,0,0,30747000,0,-4000,,-30751000,-30751000,419353000.0,14869000.0,77270000.0,2000000.0,92139000.0,52000.0,-342135000.0,,70000.0,91431000.0,14869000.0,92049000.0,,,8743000.0,20000.0,,6633000.0,-8000.0,73265000.0,-609000.0,73273000.0,49702000.0,-23543000.0,-5010000.0,1184000.0,-20000.0,77180000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,16.71,1630526403,0.12999916,16.3752,16.91,16.12,579568,USD,NCM,987288576,-14400000,False,False,PRE,2,0.78407216,16.12 - 16.91,us_market,0,"Humanigen, Inc.",16.58,0.0,0.0,10,14,finmb_6099166,NasdaqCM,"Humanigen, Inc.",USD,1119707,859085,9.209999,1.2279999,7.5 - 29.2,-12.490002,-0.42773977,7.5,29.2,1600041600,1620921660,1628798400,1629144000,-3.437,4.11,0.04,417.75,0.317,16.589714,0.120285034,0.007250579,17.594275,-0.88427544,-0.050259273,4.065693,52.71293,15,America/New_York,EDT,-2.37,,,29.2,7.5,16.59,17.59,1.12M,859.09k,59.08M,,44.37M,23.35%,39.16%,7.49M,5.47,19.83%,12.69%,7.16M,,,,,,0.00%,"Sep 13, 2020",,1:5,"Sep 13, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-18,864.29%",-189.54%,"-41,589.92%",798k,0.02,,312k,,-152.64M,-3.44,,92.89M,1.57,24.44M,143.59,1.85,0.32,-105.07M,-53.72M,Value,94005,Healthcare,10,"Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.",Burlingame,650 243 3100,CA,1609372800,United States,http://www.humanigen.com,86400,533 Airport Boulevard,Biotechnology,Suite 400
t-3,HGEN,31601000.0,59083700,21143000,,-24022000,,-24022000,1956000,0,-23099000,-23099000,,-923000,,,,0,0,23099000,0,-923000,,-24022000,-24022000,342775000.0,10968000.0,31601000.0,2000000.0,42569000.0,210000.0,-311384000.0,,70000.0,41729000.0,10968000.0,42499000.0,,,2110000.0,,8000.0,-3796000.0,-3336000.0,63668000.0,5367000.0,67004000.0,41660000.0,-22008000.0,-5010000.0,443000.0,-20000.0,31531000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,16.71,1630526403,0.12999916,16.3752,16.91,16.12,579568,USD,NCM,987288576,-14400000,False,False,PRE,2,0.78407216,16.12 - 16.91,us_market,0,"Humanigen, Inc.",16.58,0.0,0.0,10,14,finmb_6099166,NasdaqCM,"Humanigen, Inc.",USD,1119707,859085,9.209999,1.2279999,7.5 - 29.2,-12.490002,-0.42773977,7.5,29.2,1600041600,1620921660,1628798400,1629144000,-3.437,4.11,0.04,417.75,0.317,16.589714,0.120285034,0.007250579,17.594275,-0.88427544,-0.050259273,4.065693,52.71293,15,America/New_York,EDT,-2.37,,,29.2,7.5,16.59,17.59,1.12M,859.09k,59.08M,,44.37M,23.35%,39.16%,7.49M,5.47,19.83%,12.69%,7.16M,,,,,,0.00%,"Sep 13, 2020",,1:5,"Sep 13, 2020","Dec 30, 2020","Mar 30, 2021",0.00%,"-18,864.29%",-189.54%,"-41,589.92%",798k,0.02,,312k,,-152.64M,-3.44,,92.89M,1.57,24.44M,143.59,1.85,0.32,-105.07M,-53.72M,Value,94005,Healthcare,10,"Humanigen, Inc., a clinical stage biopharmaceutical company, develops a portfolio of immuno-oncology and immunology monoclonal antibodies in the United States. The company's lead product candidate is Lenzilumab, a monoclonal antibody that targets and neutralizes human granulocyte-macrophage colony-stimulating factor, which is in Phase III clinical trial for the treatment of cytokine storm associated with COVID-19; and Phase Ib/II clinical trial as a sequenced therapy in combination with CD19 targeted chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory B-cell lymphoma, as well as that has completed Phase I clinical trial in patients with chronic myelomonocytic leukemia. It also develops Ifabotuzumab, a humaneered monoclonal antibody that targets EphA3 receptor, which has completed the Phase I dose escalation portion of a Phase I/II clinical trial in multiple hematologic malignancies; and HGEN005, an anti-EMR1 monoclonal antibody, which is in pre-clinical stage for the treatment of eosinophilic disorders. Humanigen, Inc. has a clinical collaboration agreement with Kite Pharma, Inc. to conduct a multi-center Phase Ib/II study of Lenzilumab in patients with relapsed or refractory diffuse large B-cell lymphoma; and a cooperative research and development agreement with the Department of Defense to assist in the development of lenzilumab in advance of a potential emergency use authorization for COVID-19. The company was formerly known as KaloBios Pharmaceuticals, Inc. and changed its name to Humanigen, Inc. in August 2017. Humanigen, Inc. was incorporated in 2000 and is based in Burlingame, California.",Burlingame,650 243 3100,CA,1609372800,United States,http://www.humanigen.com,86400,533 Airport Boulevard,Biotechnology,Suite 400
